trending Market Intelligence /marketintelligence/en/news-insights/trending/4hzshp6n0izvzsczzu0ylg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

India's Zydus Healthcare acquires six drug brands from Merck

Independent Networks Gain Little Traction On Virtual Multichannel Services

Big Strategy Decisions Ahead For Viacom As It Moves Into The CBS Fold

Street Talk Episode 48 - Bank M&A, Investing Against An Inverted Yield Curve Overview

Asia OTT Leaders Continue To Expand Partnerships With Telcos


India's Zydus Healthcare acquires six drug brands from Merck

India's Zydus Healthcare Ltd. acquired six brands from Merck & Co. Inc. that fall under the categories of men's health, women's health, wound management and cardiovascular therapy.

The brands are Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten, which had sales of 840 million Indian rupees in 2015.

The companies did not disclose the financial terms of the acquisition.

As of Dec. 28, US$1 was equivalent to 68.21 Indian rupees.